Etaracizumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Etaracizumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
Targetalpha-v beta-3 integrin
Clinical data
Trade namesAbegrin
ATC code
  • none
Identifiers
CAS Number
  • 892553-42-3 ☒N
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6392H9908N1732O1996S42
Molar mass144302.22 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Etaracizumab, also known as etaratuzumab,[citation needed] MEDI-522, trade name Abegrin, is a humanized monoclonal antibody which is being investigated for the treatment of metastatic melanoma, prostate cancer,[1] ovarian cancer[2] and various other types of cancer.[3] It is manufactured by MedImmune.[1]

It is an enhanced iteration of Vitaxin, also known as MEDI-523. Both are derived from the mouse antibody LM609.[4]

References[edit]

  1. ^ a b "Etaracizumab" (PDF). Statement On A Nonproprietary Name Adopted By The Usan Council.
  2. ^ Landen CN, Kim TJ, Lin YG, Merritt WM, Kamat AA, Han LY, et al. (November 2008). "Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer". Neoplasia. 10 (11): 1259–67. doi:10.1593/neo.08740. PMC 2570602. PMID 18953435.
  3. ^ Delbaldo C, Raymond E, Vera K, Hammershaimb L, Kaucic K, Lozahic S, et al. (February 2008). "Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors". Investigational New Drugs. 26 (1): 35–43. doi:10.1007/s10637-007-9077-0. PMID 17876527. S2CID 37221398.
  4. ^ McNeel DG, Eickhoff J, Lee FT, King DM, Alberti D, Thomas JP, et al. (November 2005). "Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion". Clinical Cancer Research. 11 (21): 7851–60. doi:10.1158/1078-0432.CCR-05-0262. PMID 16278408.